What predicts poor outcome after successful thrombectomy in early time window?
- PMID: 34750109
- DOI: 10.1136/neurintsurg-2021-017946
What predicts poor outcome after successful thrombectomy in early time window?
Abstract
Background: Half of the patients with large vessel occlusion (LVO)-related acute ischemic stroke (AIS) who undergo endovascular reperfusion are dead or dependent at 3 months. We hypothesize that in addition to established prognostic factors, baseline imaging profile predicts outcome among reperfusers.
Methods: Consecutive patients receiving endovascular treatment (EVT) within 6 hours after onset with Thrombolysis In Cerebral Infarction (TICI) 2b, 2c and 3 revascularization were included. Poor outcome was defined by a modified Rankin scale (mRS) 3-6 at 90 days. No mismatch (NoMM) profile was defined as a mismatch (MM) ratio ≤1.2 and/or a volume <10 mL on pretreatment imaging.
Results: 187 patients were included, and 81 (43%) had a poor outcome. Median delay from stroke onset to the end of EVT was 259 min (IQR 209-340). After multivariable logistic regression analysis, older age (OR 1.26, 95% CI 1.06 to 1.5; p=0.01), higher National Institutes of Health Stroke Scale (NIHSS) (OR 1.15, 95% CI 1.06 to 1.25; p<0.0001), internal carotid artery (ICA) occlusion (OR 3.02, 95% CI 1.2 to 8.0; p=0.021), and NoMM (OR 4.87, 95% CI 1.09 to 22.8; p=0.004) were associated with poor outcome. In addition, post-EVT hemorrhage (OR 3.64, 95% CI 1.5 to 9.1; p=0.04) was also associated with poor outcome.
Conclusions: The absence of a penumbra defined by a NoMM profile on baseline imaging appears to be an independent predictor of poor outcome after reperfusion. Strategies aiming to preserve the penumbra may be encouraged to improve these patients' outcomes.
Keywords: CT perfusion; MRI; thrombectomy.
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: JMO Medtronic, Aptoll, Abbvie, BMS-Pfizer, Medtronic French Ministry of Health. JJH Ischema View, Medtronic, Microvention. LC Boehringer Ingelheim, BMS-Pfizer, Boehringer. NR Fullbright Foundation, Harvard University and Philippe Foundation. MMa Boerhinger Ingelheim, Medtronic, Air Liquide, Amgen, Acticor Biotech. AG Member of Editorial Board JNIS Fellows. IS AstraZeneca, BMS-Pfizer, Bayer, Boehringer Ingelheim, Medtronic, NovoNordisc. TT Canon Medical, grant from French research secretary. GWA IschemaView, Genentech, grant from NIHCC Medtronic Cerenovus Stryker MIVI Neuroscience, Microvention. SC IschemaView.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous